He Guanghui, Zhang Liping, Guo Lei, Han Aiqiang
Department of Interventional Department, Weifang No. 2 People's Hospital, Weifang, China.
Department of Vascular Anomalies and Interventional Radiology, Children's Hospital Affiliated to Shandong University, Jinan, China.
Front Surg. 2025 May 13;12:1565333. doi: 10.3389/fsurg.2025.1565333. eCollection 2025.
To investigate the treatment outcomes of sclerotherapy with pingyangmycin and polidocanol for venous malformations.
This retrospective study included patients with venous malformations who underwent sclerotherapy between January 2022 and June 2024. Patient demographics, symptoms, treatment information were gathered from the electronic medical records, and imaging data from the hospital's picture archiving and communication system were reviewed.
A total of 29 patients, composed of 12 males and 17 females, with venous malformations, who underwent 66 procedures during the study period, were analyzed. The lesions were located in the lower limbs in 13 cases, in the upper limbs in 9, in the head and neck in 5, and in the trunk in 2. Twenty-four patients presented with pain, with a median visual analog scale (VAS) score of 4 and the correlation with age was statistically significant. After sclerotherapy, the median VAS score declined to 1, and there was a statistical difference in the overall median VAS score between pre- and post-treatment. According to the evaluation criteria, the treatment response was evaluated as grade 4 in 4 cases, as grade 3 in 17 cases, and as grade 2 in 8 cases; none of the treatment responses was evaluated as grade 1. None of the patients experienced serious adverse reactions.
Sclerotherapy with pingyangmycin and polidocanol is a treatment modality for relieving the clinical symptoms of venous malformations, with good efficacy and few potential risks.
探讨平阳霉素与聚多卡醇硬化治疗静脉畸形的疗效。
本回顾性研究纳入了2022年1月至2024年6月期间接受硬化治疗的静脉畸形患者。从电子病历中收集患者的人口统计学资料、症状、治疗信息，并回顾医院图像存档与通信系统中的影像数据。
共分析了29例静脉畸形患者，其中男性12例，女性17例，在研究期间共接受了66次治疗。病变位于下肢13例，上肢9例，头颈部5例，躯干2例。24例患者有疼痛症状，视觉模拟量表（VAS）评分中位数为4分，且与年龄的相关性具有统计学意义。硬化治疗后，VAS评分中位数降至1分，治疗前后总体VAS评分中位数存在统计学差异。根据评估标准，治疗反应评估为4级4例，3级17例，2级8例；无1级治疗反应。所有患者均未发生严重不良反应。
平阳霉素与聚多卡醇硬化治疗是缓解静脉畸形临床症状的一种治疗方式，疗效良好且潜在风险少。
